AMAG Pharmaceuticals, Inc. (AMAG) Given a $40.00 Price Target at Jefferies Group LLC
Jefferies Group LLC set a $40.00 price objective on AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) in a research report report published on Thursday morning. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.
Several other research firms have also recently issued reports on AMAG. Cantor Fitzgerald set a $24.00 price target on AMAG Pharmaceuticals and gave the company a hold rating in a report on Monday, February 27th. Zacks Investment Research cut AMAG Pharmaceuticals from a hold rating to a strong sell rating in a report on Monday, January 9th. Cowen and Company downgraded shares of AMAG Pharmaceuticals from an outperform rating to a market perform rating in a research note on Friday, February 3rd. Raymond James Financial, Inc. reissued an underperform rating on shares of AMAG Pharmaceuticals in a research note on Monday, January 9th. Finally, JPMorgan Chase & Co. set a $24.00 target price on shares of AMAG Pharmaceuticals and gave the company a hold rating in a research note on Tuesday, January 31st. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus target price of $32.00.
Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) traded up 0.670% during trading on Thursday, hitting $22.701. The stock had a trading volume of 344,391 shares. The firm’s 50-day moving average is $22.82 and its 200-day moving average is $26.53. AMAG Pharmaceuticals has a one year low of $17.92 and a one year high of $36.83. The firm’s market cap is $779.53 million.
AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings results on Tuesday, February 14th. The specialty pharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.24 by $0.55. The company earned $151.60 million during the quarter, compared to the consensus estimate of $155.12 million. AMAG Pharmaceuticals had a net margin of 3.12% and a return on equity of 11.10%. AMAG Pharmaceuticals’s quarterly revenue was up 39.5% on a year-over-year basis. During the same period in the prior year, the company posted $1.12 EPS. Equities research analysts forecast that AMAG Pharmaceuticals will post $6.36 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/04/21/amag-pharmaceuticals-inc-amag-given-a-40-00-price-target-at-jefferies-group-llc.html.
Institutional investors have recently bought and sold shares of the company. Clark Estates Inc. NY increased its position in AMAG Pharmaceuticals by 16.5% in the first quarter. Clark Estates Inc. NY now owns 120,100 shares of the specialty pharmaceutical company’s stock worth $2,708,000 after buying an additional 17,000 shares during the period. Louisiana State Employees Retirement System increased its position in AMAG Pharmaceuticals by 1.4% in the first quarter. Louisiana State Employees Retirement System now owns 14,000 shares of the specialty pharmaceutical company’s stock worth $316,000 after buying an additional 200 shares during the period. Fox Run Management L.L.C. bought a new position in AMAG Pharmaceuticals during the first quarter worth $992,000. Cornerstone Financial Partners LLC increased its position in AMAG Pharmaceuticals by 306.3% in the first quarter. Cornerstone Financial Partners LLC now owns 49,492 shares of the specialty pharmaceutical company’s stock worth $1,116,000 after buying an additional 37,312 shares during the period. Finally, Bank of Montreal Can increased its position in AMAG Pharmaceuticals by 4,071.4% in the first quarter. Bank of Montreal Can now owns 66,492 shares of the specialty pharmaceutical company’s stock worth $1,500,000 after buying an additional 64,898 shares during the period.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Stock Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.